Tafenoquine
Edina Avdic, Pharm.D.
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
- Two different brand names were FDA approved in 2018
- Krintafel™- radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥16 years old who are receiving appropriate antimalarial therapy for acute P. vivax infection.
- Please note that tafenoquine is NOT indicated for the treatment of acute P. vivax malaria.
- Arakoda™-prophylaxis of malaria in patients ≥18 years of age
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2025 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.